IPAMORELIN/TESAMORELIN 10mg

for: Growth Hormone Release; Muscle Recovery.

Ipamorelin / Tesamorelin 10mg Blend is a specialized research formulation combining two potent growth hormone secretagogues designed to investigate synergistic signaling within the somatotropic axis. By targeting the GHRH receptor and the ghrelin/growth hormone secretagogue receptor (GHS-R1a) simultaneously, this blend serves as a high-precision tool for exploring metabolic regulation and adipose tissue reduction. Dragon Pharma provides this 10mg blend (5mg Ipamorelin / 5mg Tesamorelin) at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of metabolic research and neuroendocrinology, few combinations offer as much utility as the Ipamorelin / Tesamorelin Blend. Tesamorelin, a stabilized analog of growth hormone-releasing hormone (GHRH), and Ipamorelin, a highly selective ghrelin mimetic, work in tandem to explore the "dual-pathway" stimulation of the pituitary gland. Dragon Pharma provides this 10mg blend at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Peptide capable of producing reproducible and accurate data in complex biological models.

As scientific inquiry into lipodystrophy, metabolic syndrome, and pituitary secretory capacity expands, the need for reliable, synergistic secretagogue blends has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of the Ipamorelin / Tesamorelin 10mg Blend.

Molecular Characteristics and Chemical Profile

The structural integrity of this blend allows for the investigation of two distinct mechanisms of action within a single experimental framework. Tesamorelin is modified with a trans-3-hexenoic acid group to increase its resistance to enzymatic cleavage, while Ipamorelin is engineered for extreme receptor selectivity.

• Chemical Identity (1): Tesamorelin (GHRH Analog)
• Chemical Identity (2): Ipamorelin (GHS-R1a Agonist)
• Molecular Formula: C223H370N72O69S (Tesamorelin) | C₃₈H₄₉N₉O₅ (Ipamorelin)
• Molecular Weight: 5135.9 g/mol (Tesamorelin) | 711.85 g/mol (Ipamorelin)
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The peptide blend is utilized in various scientific investigative domains, including:

• Adipose Tissue Metabolism: Mapping the pathways of visceral fat reduction and lipolysis.
• Pulsatile GH Signaling: Investigating the amplitude and frequency of growth hormone secretion.
• Glucose Homeostasis: Studying the modulation of insulin sensitivity and carbohydrate metabolism.
• Pituitary Reserve: Assessing the maximal secretory capacity of somatotroph cells.
• Cognitive Research: Evaluating the impact of GHRH analogs on proteostasis and neuroprotection in aging models.

Pathway and Mechanistic Context

The core value of the Ipamorelin / Tesamorelin 10mg Blend in a laboratory setting is its ability to manipulate the growth hormone axis through two complementary pathways. In a natural physiological state, GH release is triggered by GHRH and inhibited by somatostatin. This blend bypasses inhibitors while maximizing stimulatory input.

The GHRHR and GHS-R1 Axis

1. Tesamorelin: Binds to GHRH receptors, stimulating the synthesis and secretion of endogenous growth hormone.
2. Ipamorelin: Binds to the ghrelin receptor, facilitating a calcium-dependent release of GH while simultaneously inhibiting somatostatin.

Key Mechanistic Shifts:

• Synergistic Secretion: The combination is researched for its ability to elicit a significantly higher GH pulse than either peptide alone.
• Selective Lipolysis: Tesamorelin is specifically studied for its impact on visceral adipose tissue (VAT) and its ability to improve lipid profiles.
• Minimal Off-Target Effects: Unlike other secretagogues, Ipamorelin ensures that the blend does not significantly increase prolactin or cortisol levels, maintaining experimental purity.

Primary Research Applications

1. Visceral Adiposity and Lipodystrophy Research

This blend is heavily utilized in studies involving metabolic dysfunction. Because Tesamorelin specifically targets abdominal fat while Ipamorelin supports lean mass maintenance, it provides a unique framework for investigating the reversal of metabolic syndrome.

2. IGF-1 Modulation and Tissue Repair

Known in research circles for its anabolic potential, the blend is used to observe how tissues adapt to sustained elevations in the IGF-1 axis. Investigators study changes in protein synthesis and the rate of musculoskeletal recovery in injury models.

3. Growth Hormone Pulse Dynamics

In endocrine research, this combination is studied for its ability to mimic the natural, pulsatile rhythm of GH release. Labs focus on how this rhythm as opposed to a static elevation impacts long-term receptor sensitivity and metabolic health.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process. Every Ipamorelin / Tesamorelin 10mg vial is produced under strict laboratory conditions to ensure each component is present in its correct ratio.

• Lyophilization for Stability: The blend is supplied in a freeze-dried form to preserve the molecular sequences and acylation of the Tesamorelin chain.
• Rigorous Analytical Verification: Every batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to guarantee a purity level of 99%+ and verify that no synthesis byproducts remain.

Product Usage Disclaimer: This product is intended for laboratory and in-vitro research use only. It is not approved for human or veterinary application. Must be handled by qualified professionals. Not for drug, food, or cosmetic purposes. Misuse or misbranding is strictly prohibited.